or Try an Advanced Search...

    Halozyme Stocks List

    Symbol Grade Name % Change
    HALO F Halozyme Therapeutics, Inc. -0.85
    NXTC F NextCure, Inc. -1.54
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Halozyme stocks.

    Symbol Grade Name Weight
    FBT D First Trust Amex Biotech Index Fund 3.44
    CSMD B Congress SMid Growth ETF 2.45
    PBE D PowerShares Dynamic Biotech & Genome 2.42
    FFND A The Future Fund Active ETF 1.44
    BBP C BioShares Biotechnology Products Fund 1.38
    View all Halozyme ETFs...
    Compare ETFs
    Compare CSMD to BBP Compare CSMD to FFND Compare FBT to FFND

        Halozyme Stocks Recent News

        Date Stock Title
        Nov 20 HALO Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
        Nov 19 HALO 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
        Nov 19 HALO HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
        Nov 19 HALO Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
        Nov 19 HALO Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
        Nov 19 NXTC Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
        Nov 18 HALO Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
        Nov 17 HALO Halozyme plans to finance $2.1B takeover of Evotech in cash: report
        Nov 17 HALO Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
        Nov 15 HALO Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
        Nov 15 HALO Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
        Nov 15 HALO Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
        Nov 15 HALO Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
        Nov 15 HALO Halozyme bids for Evotec; BeiGene gets a new name
        Nov 14 HALO Germany’s Evotec Gets Takeover Interest From Halozyme
        Nov 14 HALO Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
        Nov 14 HALO Evotec jumps as Halozyme confirms takeover interest (updated)
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine
        Halozyme

        Halozyme Therapeutics is a U.S. biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.
        The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

        More about Halozyme
        Browse All Tags